CL2017000367A1 - Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina - Google Patents
Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolinaInfo
- Publication number
- CL2017000367A1 CL2017000367A1 CL2017000367A CL2017000367A CL2017000367A1 CL 2017000367 A1 CL2017000367 A1 CL 2017000367A1 CL 2017000367 A CL2017000367 A CL 2017000367A CL 2017000367 A CL2017000367 A CL 2017000367A CL 2017000367 A1 CL2017000367 A1 CL 2017000367A1
- Authority
- CL
- Chile
- Prior art keywords
- prepare
- synthetic intermediates
- tetrahydroquinoline derivatives
- preparing synthetic
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000367A1 true CL2017000367A1 (es) | 2018-02-09 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000367A CL2017000367A1 (es) | 2014-08-12 | 2017-02-10 | Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (https=) |
| EP (2) | EP3180314B1 (https=) |
| JP (1) | JP6670310B2 (https=) |
| KR (1) | KR102572626B1 (https=) |
| CN (1) | CN107108558B (https=) |
| AR (1) | AR101509A1 (https=) |
| AU (1) | AU2015302407B2 (https=) |
| BR (1) | BR112017002873B1 (https=) |
| CA (1) | CA2958040C (https=) |
| CL (1) | CL2017000367A1 (https=) |
| CY (1) | CY1125574T1 (https=) |
| DK (1) | DK3180314T3 (https=) |
| EA (1) | EA034357B1 (https=) |
| ES (1) | ES2926775T3 (https=) |
| HR (1) | HRP20221061T1 (https=) |
| HU (1) | HUE059947T2 (https=) |
| IL (1) | IL250525B (https=) |
| LT (1) | LT3180314T (https=) |
| MA (1) | MA40378B1 (https=) |
| MX (1) | MX367908B (https=) |
| PL (1) | PL3180314T3 (https=) |
| PT (1) | PT3180314T (https=) |
| RS (1) | RS63575B1 (https=) |
| SG (1) | SG11201701077XA (https=) |
| SI (1) | SI3180314T1 (https=) |
| SM (1) | SMT202200385T1 (https=) |
| TW (1) | TWI691490B (https=) |
| WO (1) | WO2016024858A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4125911B1 (en) | 2021-03-05 | 2024-04-24 | NewAmsterdam Pharma B.V. | Obicetrapib for treatment of dementias |
| IL310115A (en) | 2021-07-26 | 2024-03-01 | Newamsterdam Pharma B V | Treatment of his hyporesponders |
| AU2022425078A1 (en) | 2021-12-30 | 2024-08-08 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| CU20250001A7 (es) | 2022-07-05 | 2025-10-17 | Newamsterdam Pharma B V | Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos |
| TW202416994A (zh) | 2022-08-22 | 2024-05-01 | 荷蘭商新阿姆斯特丹製藥公司 | 固定劑量醫藥組合物及其用途 |
| EP4661865A1 (en) | 2023-02-07 | 2025-12-17 | NewAmsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| WO2026062050A1 (en) | 2024-09-17 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
| WO2026062049A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V., | Obicetrapib for the treatment of dementias |
| WO2026063944A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for the treatment of dementias |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| ATE316957T1 (de) * | 2001-04-30 | 2006-02-15 | Pfizer Prod Inc | Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
| TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
-
2015
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en not_active Ceased
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
-
2022
- 2022-09-22 CY CY20221100631T patent/CY1125574T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000367A1 (es) | Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina | |
| SG10201806846RA (en) | Cyclopropylamines as lsd1 inhibitors | |
| PH12016501601A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| SG11201610028TA (en) | Compositions and methods of delivering treatments for latent viral infections | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
| EP3122782A4 (en) | Compositions and methods for treatment of diabetic macular edema | |
| EP3186278A4 (en) | Internalizing moieties for treatment of cancer | |
| EP3151818A4 (en) | Compositions and methods of treating diabetic retinopathy | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| BR112016025792A2 (pt) | meios e processos para tratamento de cmv | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| SG11201607996SA (en) | Effect of lipophilic nutrients on diabetic eye diseases | |
| SI3116519T1 (sl) | Topični sestavki, ki obsegajo izvleček coriolusa versicolora za izboljšanje avtoimunosti | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| EP3322406A4 (en) | TRANSPAPILLARY METHOD AND COMPOSITION FOR THE TREATMENT OF BREAST DISEASES | |
| EP3145532A4 (en) | Individualized treatment of eye disease | |
| ZA201608607B (en) | Novel fluoroquinolones and use thereof to treat bacterial infections | |
| PL3142641T3 (pl) | Preparaty do leczenia nadczynności tarczycy | |
| EP3122867A4 (en) | Preparation of small colony variants of therapeutic bacteria | |
| EP3393462A4 (en) | COMPOSITIONS AND METHODS FOR TREATING, REDUCING AND PREVENTING NARCOSE-INDUCED HYPOTHERMIA | |
| EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
| EP3148563A4 (en) | Methods and compositions for enhancement of ability to concentrate | |
| IN2014CH01391A (https=) | ||
| HK1262958A1 (en) | Compositions and methods for treatment of eye diseases |